FOI:2022/525

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

·       Nivolumab (monotherapy)

·       Nivolumab AND Ipilimumab (combination)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Melanoma is treated at the cancer centre (LTHTR).  We do not treat at ELHT and no data available.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma?

·       Nivolumab (monotherapy)

·       Nivolumab + Ipilimumab

·       Nivolumab + Cabozantinib

·       Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

 We have used the following diagnoses to obtain these figures:

- Renal cell carcinoma
- Renal
- Malignant neoplasm of unspecified kidney, except renal pelvis 

Data below of patients. 
 

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of upper gastrointestinal cancer (oesophagael cancer, gastric cancer and gastro-oesophageal junction cancer)?

·       Nivolumab

·       Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

IQemo doesn't differentiate well for upper gastrointestinal cancer.
 

We have used the following diagnoses to obtain these figures:

- Oesophagus

- Gastro-oesophageal junction
- Gastro-oesophageal cancer
- Gastro-intestinal stromal tumour